Pre-Market
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
The first-quarter earnings season has come to an end for large drug and biotech companies, with Bayer reporting its results earlier this week. Per ...
TreeHouse Foods (THS) Looks Resilient on Private-Label Strength
TreeHouse Foods, Inc. THS appears to be at the crossroads of promising opportunities and pressing challenges as it moves through 2024. Let’s delve deeper ...
Reasons Why Investors Should Bet on RLI Stock Right Now
RLI Corp.’s RLI compelling product portfolio, rate increases, improved retention, higher premium receipts and sufficient liquidity make it worth adding to one’s portfolio. Optimistic ...
Nu Skin (NUS) Q1 Earnings Beat, Revenues Hurt by Currency Woes
Nu Skin Enterprises, Inc. NUS posted first-quarter 2024 results, wherein both the top and bottom lines declined year over year, and revenues missed the ...
Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y
Shockwave Medical, Inc. SWAV reported first-quarter 2024 earnings per share (EPS) of $1.44, which beat the Zacks Consensus Estimate of $1.04 by 38.46%. The company ...
Tyson Foods (TSN) Q2 Earnings Top Estimates Despite Lower Sales
Tyson Foods, Inc. TSN posted second-quarter fiscal 2024 results, wherein the top line declined year over year and fell short of the Zacks Consensus ...
Why Earnings Season Could Be Great for BioNTech (BNTX)
Investors are always looking for stocks that are poised to beat at earnings season and BioNTech SE BNTX may be one such company. The ...
West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak
West Pharmaceutical Services, Inc. WST reported first-quarter 2024 adjusted earnings per share (EPS) of $1.56, which beat the Zacks Consensus Estimate by 20.9%. The ...
4 Large Drug Stocks to Hold on to Amid Industry Challenges
After a rather weak 2023, the drug and biotech sector made a comeback initially in 2024 amid a slew of takeover deals. However, the ...
Tesla Pre EPS Turmoil: 3 Long-Term Factors to Consider
Beyond Bitcoin, finding a more controversial, “battleground” investment than Tesla (TSLA) is difficult.Depending on whom you ask and their investment timeframe, the stock is ...
